...
akro-img

Akero Therapeutics Inc, Common Stock

AKRO

NSQ

$27.554

-$1.16

(-4.04%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.14B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
40.87K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.26
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$15.32 L
$37 H
$27.554

About Akero Therapeutics Inc, Common Stock

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAKROSectorS&P500
1-Week Return-5.4%-3.39%-3.47%
1-Month Return-2.88%-3.25%-0.29%
3-Month Return6.49%-11.61%4.5%
6-Month Return29.56%-5.89%6.91%
1-Year Return30.56%2.65%23.79%
3-Year Return32.98%0.56%28.43%
5-Year Return47.99%34.63%83.64%
10-Year Return56.71%94.78%185.94%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue-80.15M100.89M260.00K29.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":79.45,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.26,"profit":true},{"date":"2023-12-31","value":0.03,"profit":true}]
Gross Profit-(80.15M)(100.89M)(260.00K)(29.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8015400000,"profit":false},{"date":"2021-12-31","value":-10088600000,"profit":false},{"date":"2022-12-31","value":-26000000,"profit":false},{"date":"2023-12-31","value":-2900000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses45.65M80.15M100.89M115.16M172.87M[{"date":"2019-12-31","value":26.41,"profit":true},{"date":"2020-12-31","value":46.37,"profit":true},{"date":"2021-12-31","value":58.36,"profit":true},{"date":"2022-12-31","value":66.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(45.65M)(80.15M)(100.89M)(115.16M)(172.87M)[{"date":"2019-12-31","value":-4565100000,"profit":false},{"date":"2020-12-31","value":-8015400000,"profit":false},{"date":"2021-12-31","value":-10088600000,"profit":false},{"date":"2022-12-31","value":-11515600000,"profit":false},{"date":"2023-12-31","value":-17287000000,"profit":false}]
Total Non-Operating Income/Expense--218.00K2.38M18.55M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":1.18,"profit":true},{"date":"2022-12-31","value":12.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(43.76M)(79.21M)(100.78M)(112.03M)(151.76M)[{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7920700000,"profit":false},{"date":"2021-12-31","value":-10077700000,"profit":false},{"date":"2022-12-31","value":-11203300000,"profit":false},{"date":"2023-12-31","value":-15175900000,"profit":false}]
Income Taxes(1.90M)(17.00K)(41.00K)(3.12M)-[{"date":"2019-12-31","value":-189600000,"profit":false},{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-4100000,"profit":false},{"date":"2022-12-31","value":-312300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes--(100.74M)(108.91M)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-10073600000,"profit":false},{"date":"2022-12-31","value":-10891000000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(43.76M)(79.21M)(100.80M)(111.97M)(119.63M)[{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7920700000,"profit":false},{"date":"2021-12-31","value":-10080100000,"profit":false},{"date":"2022-12-31","value":-11196900000,"profit":false},{"date":"2023-12-31","value":-11963200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(43.76M)(79.19M)(100.74M)(108.91M)(151.76M)[{"date":"2019-12-31","value":-4375500000,"profit":false},{"date":"2020-12-31","value":-7919000000,"profit":false},{"date":"2021-12-31","value":-10073600000,"profit":false},{"date":"2022-12-31","value":-10891000000,"profit":false},{"date":"2023-12-31","value":-15175900000,"profit":false}]
EPS (Diluted)(3.55)(2.48)(2.89)(2.92)(2.85)[{"date":"2019-12-31","value":-354.63,"profit":false},{"date":"2020-12-31","value":-248,"profit":false},{"date":"2021-12-31","value":-289,"profit":false},{"date":"2022-12-31","value":-292,"profit":false},{"date":"2023-12-31","value":-285,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AKRO
Cash Ratio 16.57
Current Ratio 17.25

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AKRO
ROA (LTM) -23.17%
ROE (LTM) -35.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AKRO
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AKRO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.76
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Akero Therapeutics Inc share price today?

Akero Therapeutics Inc (AKRO) share price today is $27.554

Can Indians buy Akero Therapeutics Inc shares?

Yes, Indians can buy shares of Akero Therapeutics Inc (AKRO) on Vested. To buy Akero Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AKRO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Akero Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Akero Therapeutics Inc (AKRO) via the Vested app. You can start investing in Akero Therapeutics Inc (AKRO) with a minimum investment of $1.

How to invest in Akero Therapeutics Inc shares from India?

You can invest in shares of Akero Therapeutics Inc (AKRO) via Vested in three simple steps:

  • Click on Sign Up or Invest in AKRO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Akero Therapeutics Inc shares
What is Akero Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Akero Therapeutics Inc (AKRO) is $37. The 52-week low price of Akero Therapeutics Inc (AKRO) is $15.32.

What is Akero Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Akero Therapeutics Inc (AKRO) is

What is Akero Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Akero Therapeutics Inc (AKRO) is 2.76

What is Akero Therapeutics Inc dividend yield?

The dividend yield of Akero Therapeutics Inc (AKRO) is 0.00%

What is the Market Cap of Akero Therapeutics Inc?

The market capitalization of Akero Therapeutics Inc (AKRO) is $2.14B

What is Akero Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Akero Therapeutics Inc is AKRO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top